Indeed, clinical trials of anti-PD-1/PD-L1 monotherapies in prostate cancer have exhibited limited benefit thus far, including a recent phase III randomized clinical trial of atezolizumab failing to meet its primary overall survival (OS) endpoint14–17. Here, CD274 is linked to prostate cancer.